The Critical Care Response to the COVID-19 Pandemic in Madrid

NCT ID: NCT04393324

Last Updated: 2020-05-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-24

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Description of the adaptation of ICUs in the region of Madrid to que surge in demand of critical care due to COVID-19

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background

The worldwide SARS-CoV-2 pandemic has put healthcare systems under the extreme pressure, with intensive care units being faced with a previously unseen number of patients with severe respiratory failure requiring admission for endotracheal intubation and mechanical ventilation.

Methods

The study describes how the critical care resources adapted to the sudden surge of severe Covid-19 in the province of Madrid, which developed at the beginning of March 2020. The response consisted of a swift increase in ICU capacity and the relocation of patients. ICU beds were mounted outside the usual intensive care areas. Transfer of critically ill intubated patients with COVID-19 was managed in an instant messenger service group composed of representatives of 53 intensive care units and performed by the Madrid Emergency Medical Systems (EMS). The investigators will compare transferred with non-transferred patients matched for risk factors for cardiovascular and respiratory complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 ARDS, Human

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transferred patients

A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds

No interventions assigned to this group

Matched Non-transferred patients

A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted to ICU in Madrid with COVID-19

Exclusion Criteria

* Admitted to ICU without COVID-19
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

FUNDACION PARA LA INVESTIGACION HOSPITAL CLINICO SAN CARLOS

OTHER

Sponsor Role collaborator

Hospital San Carlos, Madrid

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Miguel Sanchez Garcia

Director Critical Care

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Miguel Sánchez García, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital San Carlos, Madrid

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Clinico San Carlos

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Miguel S Sanchez Garcia, MD

Role: CONTACT

+34913303223

Antonio S Núñez Reiz

Role: CONTACT

+34913303223

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Miguel Sanchez Garcia, MD. PhD

Role: primary

913303223

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Madrid COVID Tetrix

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.